Skip to Main Content

U.K. officials and Vertex Pharmaceuticals (VRTX) have finally put to rest a years-long battle over access to cystic fibrosis treatments, which came to symbolize the growing clash between cash-strapped governments and the pharmaceutical industry over the cost of medicines.

The four-year deal calls for government reimbursement for a new triple-combination therapy, which has the potential to treat 90% of cystic fibrosis patients. In turn, the drug maker has agreed to provide evidence for the medication, along with two older treatments, to a cost-effectiveness watchdog agency. The pricing and timetable for Vertex to submit the data were not disclosed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!